A one-time CRISPR gene-editing treatment has kept cholesterol and triglyceride levels sharply lower for a full year after a single infusion, according to new one-year results from a first-in-human trial led by the Cleveland Clinic. The findings, presented at the 2026 European Society of Cardiology congress, mark one of the longest follow-up periods yet reported for an in-body CRISPR therapy aimed at heart disease.
The Phase 1 study followed 15 adults with difficult-to-treat lipid disorders who had not responded adequately to existing cholesterol medications. Unlike daily pills or repeated injections, the experimental drug, known as CTX310, is designed to be given once.
What the One-Year Results Show
Participants who received the highest dose saw durable improvements that held steady well beyond the two-month mark first reported earlier in the trial:
- 52.5% reduction in LDL (“bad”) cholesterol from baseline at 12 months
- 47.8% drop in triglycerides over the same period
- Benefits measured in 15 trial participants followed for a full year
- No serious adverse events linked to the therapy itself during follow-up
How the Gene-Editing Treatment Works
CTX310 uses tiny lipid nanoparticles, fat-based delivery capsules, to carry a CRISPR-Cas9 editing system directly into liver cells. Once inside, it switches off a single gene called ANGPTL3, which normally helps regulate how much LDL cholesterol and triglycerides circulate in the blood. Silencing that gene permanently lowers both, without requiring the patient to keep taking medication.
This single-dose approach sits alongside a broader wave of health technology aimed at catching cardiovascular risk earlier, from wearable monitors to AI tools that flag hidden heart disease from a routine ECG.
Why a Single Dose Matters
Statins and injectable cholesterol drugs only work as long as patients keep taking them, and missed doses are common. A therapy that edits the underlying gene once and keeps working for at least a year, researchers say, could remove that adherence problem entirely for people whose cholesterol stays dangerously high despite standard treatment.
The approach is part of a wider push toward consumer and clinical devices that intervene earlier on health risks, a trend also visible in products like AI-powered health gadgets launched this year, even if gene editing operates on a far more fundamental level than any wearable or smart device.
Safety Profile and What Happens Next
Three participants had minor infusion-related reactions, including back pain and nausea, that resolved with medication. One participant with elevated liver enzymes at screening had a temporary further rise that returned to normal on its own within days, without additional treatment. Researchers stress this remains an early-stage, 15-person trial: larger, placebo-controlled studies are needed before the therapy could be considered for wider use. The results were published alongside the conference presentation in the New England Journal of Medicine.
The trial adds to a fast-moving year for 2026’s most talked-about health and technology innovations, as gene-editing moves from rare-disease treatment toward common conditions like high cholesterol that affect hundreds of millions of people worldwide.
For more on how science and technology stories are reshaping everyday health, see our Science and Technology coverage, and for the bigger policy and research picture, visit our National – International News section.
Questions fréquentes
What is CTX310?
CTX310 is an experimental CRISPR-Cas9 gene-editing therapy that uses lipid nanoparticles to switch off the ANGPTL3 gene in liver cells, lowering LDL cholesterol and triglycerides after a single infusion.
How long do the effects last?
In the Cleveland Clinic trial, the highest dose kept LDL cholesterol and triglycerides significantly reduced for a full 12 months after one infusion, the longest follow-up reported for this therapy so far.
Is the treatment available to patients now?
No. CTX310 has only completed a small first-in-human Phase 1 trial with 15 participants. Larger studies are still needed before regulators could consider approving it for wider use.
Sources
This article was written with the help of artificial intelligence. Editorial policy
